These additional markers were identified in only one article within our systematic review, reporting the downregulation of MCAM (CD146) in glioblastoma 24, CLDN11 (claudin 11) in colon cancer 82, and TJP2 in melanoma and breast cancer 25. Here, CLDN11 is linked to breast cancer.